Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia : A retrospective case-control study
Zsófia Klára Németh, Anna Szűcs, József Vitrai, Dóra Juhász, János Pál Németh, Dr András Holló
Ideggyógyászati szemle, doi:10.18071/isz.74.0389
Az alábbi dokumentumot magáncélra töltötték le az eLitMed.hu webportálról. A dokumentum felhasználása a szerzôi jog szabályozása alá esik. Kulcsszavak: fluoxetin, COVID-19, SARS-CoV-2, pneumonia, túlélés, mortalitás score did not show statistical difference between the fluoxetine and non-fluoxetine groups supporting the reliability of our finding. Conclusion -Provisional to confirmation in randomised controlled studies, fluoxetine may be a potent treatment increasing the survival for COVID-19 pneumonia.
References
Baldwin, Woods, Lawson, Taylor, Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis, BMJ,
doi:10.1136/bmj.d1199Brambilla, Cipriani, Hotopf, Barbui, Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data, Pharmacopsychiatry,
doi:10.1055/s-2005-837806Carpinteiro, Edwards, Hoffmann, Kochs, Gripp et al., Pharmacological inhibition of acid sphin gomyelinase prevents uptake of SARS-CoV-2 by epithelial cells, Cell Rep Med,
doi:10.1016/j.xcrm.2020.100142Colombo, Colombo, Maves, Performance analysis of the national early warning score and modified early warning score in the adaptive COVID-19 Treatment Trial Cohort, Crit Care Explor
Creeden, Imami, Eby, Gillman, Becker et al., Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection, Biomed Pharmacother,
doi:10.1016/j.biopha.2021.111437Doupnik, Mitra, Feudtner, Marcus, The Influence of Comorbid Mood and Anxiety Disorders on Outcomes of Pediatric Patients Hospitalized for Pneumonia, Hosp Pediatr,
doi:10.1542/hpeds.2015-0177Ely, Dittus, Girard, Point: should benzodiazepines be avoided in mechanically ventilated patients? Yes, Chest,
doi:10.1378/chest.12-1189Fred, Kuivanen, Ugurlu, Casarotto, Levanov et al., Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro, bioRxiv,
doi:10.1101/2021.03.22.436379Glebov, Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 protection by antidepressants, bioRxiv,
doi:10.1101/2021.06.15.448391Gordon, Hiatt, Bouhaddou, Rezelj, Ulferts et al., Comparative host-coronavirus protein inter action networks reveal pan-viral disease mechanisms, Science,
doi:10.1126/science.abe9403Hashimoto, Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor, Eur Arch Psychiatry Clin Neurosci,
doi:10.1007/s00406-020-01231-xHiles, Baker, De Malmanche, Attia, Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis, Psychol Med,
doi:10.1017/S0033291712000128Hoertel, Sánchez-Rico, Vernet, Beeker, Jannot et al., Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry,
doi:10.1038/s41380-021-01021-4Jakubovski, Johnson, Nasir, Müller-Vahl, Bloch, Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders, Depress Anxiety,
doi:10.1002/da.22854Laporte, Chapelle, Caillet, Beyens, Bellet et al., Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies, Pharmacol Res,
doi:10.1016/j.phrs.2016.08.017Larici, Cicchetti, Marano, Bonomo, Storto, COVID-19 pneumonia: current evidence of chest imaging features, evolution and prognosis, Chin J Acad Radiol,
doi:10.1007/s42058-021-00068-0Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2020.22760Lundström, Isaksson, Näsman, Wester, Mår Tensson et al., Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial, Lancet Neurol,
doi:10.1016/S1474-4422(20)30219-2Obiora, Hubbard, Sanders, Myles, The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort, Thorax,
doi:10.1136/thoraxjnl-2012-202374Pérez-Cano, Moreno-Murguía, Morales-López, Crow-Buchanan, English et al., Anxiety, depression, and stress in response to the coronavirus disease-19 pandemic, Cir,
doi:10.24875/CIRU.20000561Rosen, Seki, Fernández-Castañeda, Beiter, Eccles et al., Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis, Sci Transl Med,
doi:10.1126/scitranslmed.aau5266Samuel, Seifert, Risk of bleeding in patients on fulldose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors, Ann Pharmacother,
doi:10.1177/1060028016677309Schloer, Brunotte, Goretzko, Mecate-Zambrano, Korthals et al., Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine, Emerg Microbes Infect,
doi:10.1080/22221751.2020.1829082Schloer, Brunotte, Mecate-Zambrano, Zheng, Tang et al., Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro, Br J Pharmacol,
doi:10.1111/bph.15418Sed, El-Khouly, Bar, Am, Ghorab, Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection, Pharmaceutics,
doi:10.1016/j.ijpharm.2021.121023Starke, Reissig, Petereit-Haack, Schmauder, Nienhaus et al., The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis, medRxiv,
doi:10.1101/2021.05.27.21257909Sukhatme, Reiersen, Vayttaden, Sukhatme, Flu voxamine: a review of its mechanism of action and its role in COVID-19, Front Pharmacol,
doi:10.3389/fphar.2021.652688Sultana, Crisafulli, Gabbay, Lynn, Shakir et al., Challenges for drug repurposing in the COVID-19 pandemic era, Front Pharmacol,
doi:10.3389/fphar.2020.588654Taylor, Freemantle, Geddes, Bhagwagar, Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis, Arch Gen Psychiatry,
doi:10.1001/archpsyc.63.11.1217Vai, Mazza, Colli, Foiselle, Allen et al., Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis, Lancet Psychiatry,
doi:10.1016/S2215-0366(21)00232-7Wang, Li, Shi, Que, Liu et al., Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies, Mol Psychiatry,
doi:10.1038/s41380-019-0595-xWatkins, Koch, Sherwood, Blumenthal, Davidson et al., Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease, J Am Heart Assoc,
doi:10.1161/JAHA.112.000068Zimniak, Kirschner, Hilpert, Geiger, Danov et al., The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue, Sci Rep,
doi:10.1038/s41598-021-85049-0Çağlar, Kaçer, Anxiety levels in patients admitted to the emergency department with myocardial infarction or COVID-19 pneumonia, Psychol Health Med,
doi:10.1080/13548506.2021DOI record:
{
"DOI": "10.18071/isz.74.0389",
"ISSN": [
"0019-1442",
"2498-6208"
],
"URL": "http://dx.doi.org/10.18071/isz.74.0389",
"abstract": "<jats:p>We aimed to investigate the association between fluoxetine use and the survival of hospitalised coronavirus disease (COVID-19) pneumonia patients. This retrospective case-control study used data extracted from the medical records of adult patients hospitalised with moderate or severe COVID-19 pneumonia at the Uzsoki Teaching Hospital of the Semmelweis University in Budapest, Hungary between 17 March and 22 April 2021. As a part of standard medical treatment, patients received anti-COVID-19 therapies as favipiravir, remdesivir, baricitinib or a combination of these drugs; and 110 of them received 20 mg fluoxetine capsules once daily as an adjuvant medication. Multivariable logistic regression was used to evaluate the association between fluoxetine use and mortality. For excluding a fluoxetine-selection bias potentially influencing our results, we compared baseline prognostic markers in the two groups treated versus not treated with fluoxetine. Out of the 269 participants, 205 (76.2%) survived and 64 (23.8%) died between days 2 and 28 after hospitalisation. Greater age (OR [95% CI] 1.08 [1.05–1.11], p<0.001), radiographic severity based on chest X-ray (OR [95% CI] 2.03 [1.27–3.25], p=0.003) and higher score of shortened National Early Warning Score (sNEWS) (OR [95% CI] 1.20 [1.01-1.43], p=0.04) were associated with higher mortality. Fluoxetine use was associated with an important (70%) decrease of mortality (OR [95% CI] 0.33 [0.16–0.68], p=0.002) compared to the non-fluoxetine group. Age, gender, LDH, CRP, and D-dimer levels, sNEWS, Chest X-ray score did not show statistical difference between the fluoxetine and non-fluoxetine groups supporting the reliability of our finding. Provisional to confirmation in randomised controlled studies, fluoxetine may be a potent treatment increasing the survival for COVID-19 pneumonia.</jats:p>",
"author": [
{
"affiliation": [],
"family": "Németh",
"given": "Zsófia Klára",
"sequence": "first"
},
{
"affiliation": [],
"family": "Szűcs",
"given": "Anna",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Vitrai",
"given": "József",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Juhász",
"given": "Dóra",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Németh",
"given": "János Pál",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-8855-0469",
"affiliation": [],
"authenticated-orcid": false,
"family": "Holló",
"given": "András",
"sequence": "additional"
}
],
"container-title": [
"Ideggyógyászati szemle"
],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
12,
1
]
],
"date-time": "2021-12-01T11:12:43Z",
"timestamp": 1638357163000
},
"deposited": {
"date-parts": [
[
2021,
12,
1
]
],
"date-time": "2021-12-01T11:12:47Z",
"timestamp": 1638357167000
},
"indexed": {
"date-parts": [
[
2021,
12,
2
]
],
"date-time": "2021-12-02T11:42:23Z",
"timestamp": 1638445343842
},
"is-referenced-by-count": 0,
"issn-type": [
{
"type": "print",
"value": "0019-1442"
},
{
"type": "electronic",
"value": "2498-6208"
}
],
"issue": "11-12",
"issued": {
"date-parts": [
[
2021
]
]
},
"journal-issue": {
"issue": "11-12",
"published-online": {
"date-parts": [
[
2021
]
]
},
"published-print": {
"date-parts": [
[
2021
]
]
}
},
"member": "7411",
"original-title": [],
"page": "389-396",
"prefix": "10.18071",
"published": {
"date-parts": [
[
2021
]
]
},
"published-online": {
"date-parts": [
[
2021
]
]
},
"published-print": {
"date-parts": [
[
2021
]
]
},
"publisher": "Ideggyogyaszati Szemle Journal",
"reference-count": 0,
"references-count": 0,
"relation": {},
"score": 1,
"short-container-title": [
"Ideggyogy Sz"
],
"short-title": [],
"source": "Crossref",
"subject": [
"Clinical Neurology",
"Neurology"
],
"subtitle": [],
"title": [
"Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia : A retrospective case-control study"
],
"type": "journal-article",
"volume": "74"
}
